Related coverage linked through entity extraction aliases.
Feb 27, 2026
Zydus Lifesciences launched ANYRA, India's first indigenous Aflibercept biosimilar for retinal conditions, and secured approval for a March 2026 day-one launch of generic semaglutide for diabetes and obesity treatment.
Feb 27, 2026
Eli Lilly's oral GLP-1 drug orforglipron showed superior blood sugar control and weight loss compared to oral semaglutide in a year-long trial of over 1,500 patients with type 2 diabetes.
Feb 25, 2026
Novo Nordisk announced it will reduce list prices of Wegovy, Ozempic, and Rybelsus by 35% to 50% to $675 monthly starting in 2027, aiming to regain market share from rival Eli Lilly and improve access for high-deductible patients.
Feb 20, 2026
The European Commission has approved a new 7.2 mg once-weekly maintenance dose of Wegovy (semaglutide injection) for adults with obesity, providing physicians with an additional treatment option for patients requiring further weight reduction after the 2.4 mg dose.
Feb 23, 2026
Millions of single-use GLP-1 pens may be improperly disposed of annually, while the supplement industry responds to nutritional gaps created by reduced food intake among users of drugs like Ozempic and Wegovy.
Feb 18, 2026
GLP-1 receptor agonists like semaglutide and liraglutide may improve fertility through metabolic benefits but are not recommended during pregnancy. Current guidance advises discontinuing long-acting agents at least two months before conception.
Feb 26, 2026
Zydus Lifesciences plans to launch Semaglutide injection in India after patent expiry and introduced ANYRA, India's first indigenous Aflibercept biosimilar. The USFDA cleared the company's Ahmedabad injectable facility with zero observations.
Feb 26, 2026
Semaglutide and tirzepatide represent distinct GLP-1-based weight management medications with different mechanisms of action. Clinical trials show varying weight loss outcomes, while new combination therapies undergo head-to-head testing.
Feb 26, 2026
Eli Lilly's oral GLP-1 drug orforglipron demonstrated 6-8% weight loss in type 2 diabetes patients compared to 4-5% with oral semaglutide in a phase 3 trial, though discontinuation rates were higher due to gastrointestinal side effects.
Feb 26, 2026
Oral semaglutide and the newly FDA-approved Wegovy pill are reshaping weight management by eliminating injections. Clinical trials show meaningful weight loss, while companies integrate the medications into subscription wellness programs.
Feb 25, 2026
New target trial emulation study finds GLP-1 receptor agonists associated with lower heart failure hospitalization risk versus DPP-4 inhibitors and similar risk to SGLT-2 inhibitors in type 2 diabetes patients.
Feb 25, 2026
Indian drugmaker Dr Reddy's Laboratories is preparing to launch its generic semaglutide injection under the brand name Obeda in March 2026, as patent protection expires in India. The company plans to price it up to 60% below branded products.
Feb 25, 2026
Novo Nordisk announced it will reduce the list price of its semaglutide products Ozempic, Wegovy and Rybelsus to $675 starting January 1, 2027, representing cuts of up to 50 percent from current pricing.
Feb 25, 2026
The patent for semaglutide, the active ingredient in Ozempic, expires March 20, 2026. Indian pharmaceutical companies are preparing to launch generic versions, with prices expected to be 30-50% lower than branded products.
Feb 25, 2026
Novo Nordisk will reduce prices for Wegovy, Ozempic, and Rybelsus by up to 50% starting January 2027. Meanwhile, WADA investigates potential Olympic ban on weight loss drugs, and Brazil's Anvisa reports 65 suspected deaths linked to GLP-1 medications.
Feb 25, 2026
NATCO Pharma has licensed its semaglutide generic formulation to Eris Lifesciences for the Indian market, with a launch expected in March 2026 following CDSCO approval. The partnership targets type 2 diabetes management as the molecule loses patent exclusivity in India.
Feb 24, 2026
Triple-agonist drug retatrutide has demonstrated weight loss outcomes similar to bariatric surgery in Phase 3 trials. Research shows GLP-1 drugs work through brain-mediated appetite suppression and are effective even in genetic obesity.
Feb 24, 2026
Novo Nordisk's next-generation obesity drug CagriSema achieved 23% weight reduction compared to 25.5% for Eli Lilly's tirzepatide in an 84-week trial, causing Novo shares to fall 15% and raising questions about its competitive position.
Feb 23, 2026
Microdosing GLP-1 medications like Ozempic and Wegovy has emerged as a weight-loss trend, but health experts warn there is no scientific data supporting the practice and caution about potential safety risks.
Feb 23, 2026
CagriSema demonstrated 23% weight loss in the REDEFINE 4 trial but failed to meet its primary endpoint of non-inferiority compared to tirzepatide's 25.5% weight loss. The company submitted an FDA application in December 2025 based on earlier pivotal trials.
